Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

126.50p
   
  • Change Today:
    -1.00p
  • 52 Week High: 137.50p
  • 52 Week Low: 96.00p
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 14,457
  • Market Cap: 132.54m
  • RiskGrade: 80
  • Beta: 0.10

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (m) Pre-tax (m) EPS Dividend
30-Jun-19 Interim 79.52 4.66 4.08p 1.15p

Key Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-14 169.87 3.79 8.14p 11.3 0.9 +12% 2.60p 2.8%
31-Dec-15 156.74 5.03 8.72p 10.1 1.4 +7% 2.86p 3.2%
31-Dec-16 165.27 (1.69) 8.66p 11.9 n/a -1% 3.40p 3.3%
31-Dec-17 170.29 5.82 7.93p 16.9 n/a -8% 3.50p 2.6%
31-Dec-18 165.57 8.42 9.02p 12.3 0.9 +14% 3.80p 3.4%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 169.85 13.17 9.32p 13.6 4.0 +3% 4.08p 3.2%
31-Dec-20 178.49 14.37 10.20p 12.4 1.3 +9% 4.37p 3.4%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 11.30 10.09 12.50 1.12

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Cello Health Market Data

Currency UK Pounds
Share Price 126.50p
Change Today -1.00p
% Change -0.78 %
52 Week High 137.50p
52 Week Low 96.00p
Volume 14,457
Shares Issued 104.77m
Market Cap 132.54m
Beta 0.10
RiskGrade 80

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.74% below the market average65.74% below the market average65.74% below the market average65.74% below the market average65.74% below the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Price Trend
14.93% below the market average14.93% below the market average14.93% below the market average14.93% below the market average14.93% below the market average
15% below the sector average15% below the sector average15% below the sector average15% below the sector average15% below the sector average
Income
10.91% above the market average10.91% above the market average10.91% above the market average10.91% above the market average10.91% above the market average
57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average57.14% above the sector average
Growth
32.35% below the market average32.35% below the market average32.35% below the market average32.35% below the market average32.35% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 21-Oct-2019

Time Volume / Share Price
15:55 577 @ 125.50p
11:47 7,800 @ 126.00p
10:26 3,930 @ 126.26p
08:39 900 @ 126.00p
08:39 1,250 @ 126.26p

Cello Health Key Personnel

CEO Mark Scott

Top of Page